Oral platelet IIb/IIIa inhibitors: From attractive theory to clinical failures

Journal of Thrombosis and Thrombolysis

Volumn 10, Issue 3, 2000, Pages 217-220

  Gurbel, P A ^a   Serebruany, V L ^a  

^a SINAI HOSPITAL OF BALTIMORE   (United States)

Author keywords

GPIIb IIIa; Platelet inhibitors; Platelets; Thrombosis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CELL ADHESION MOLECULE; EPTIFIBATIDE; FIBRINOGEN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; LEFRADAFIBAN; ORBOFIBAN; PADGEM PROTEIN; PYRIDINE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; SIBRAFIBAN; THROMBIN RECEPTOR ACTIVATING PEPTIDE; TIROFIBAN; XEMILOFIBAN;

CELL INTERACTION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DOSE RESPONSE; FIBRINOGEN METABOLISM; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; THROMBOSIS;

ACUTE DISEASE; ADMINISTRATION, ORAL; CLINICAL TRIALS; CORONARY DISEASE; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBOSIS;

EID: 0034524994     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026582821645     Document Type: Review

References (26)

1. Studies on the binding of an alloimmune and two murine monoclonal antibodies to the platelet glycoprotein IIb-IIIa complex receptor
2. Platelet signal transduction pathways: Could we organize them into a 'hierarchy'?
3. Overview of clinical trials of glycoprotein IIb-IIIa inhibitors in acute coronary syndromes
4. IIb/IIIa receptor blockade in acute myocardial infarction
5. XV454, a novel nonpeptide small-molecule platelet GIIb/IIIa antagonist with comparable platelet alpha(IIb)beta3-binding kinetics to c7E3
6. Functional relevance of the expression of ligand-induced binding sites in the response to platelet GP IIb/IIIa antagonists in vivo
7. A clinician's view of thrombotic disorders of the cardiovascular system
8. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy
9. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptors
10. Platelet microparticles promote platelet interaction with subendothelial matrix in a glycoprotein IIb/IIIa-dependent mechanism
11. Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects
12. Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency. Implications for assay methodology and comparison of different antagonists
13. Modulation of platelet-neutrophil interaction with pharmacological inhibition of fibrinogen binding to platelet GP IIb/IIIa receptor
14. Storing paraformaldehyde fixed whole blood patient samples after chronic platelet glycoprotein IIb/IIIa blockade:-Core laboratory considerations
15. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: Results of a multi-center, placebo-controlled, randomized trial
16. Long-term treatment with a platelet-glycorsotein-receptor antagonist after percutan eons coronary revascularization. EXCITE Trial Investigators. Evaluation of oral xemilofiban in controlling thrombotic events
17. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomized trial. Sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes
18. Oral IIb/IIIa inhibition and revascularization: Preliminary results from OPUS-TIMI 16 (Orbofiban in patients with unstable coronary syndromes)
19. Increased mortality with oral glycoprotein IIb/IIIa antagonists: A pooled analysis of the large scale oral glycoprotein IIb/IIIa trials
20. Heterogeneity of platelet aggregation and major surface receptor expression in patients presenting with acute myocardial infarction
21. Monitoring platelet inhibition after chronic oral platelet GP II/IIIa blockade: Are we missing something?
22. Role of soluble and platelet-bound P-selectin in discriminating cardiac from non-cardiac chest pain at presentation in the emergency department
23. Baseline platelet aggregation and major receptor expression predict subsequent activity following thrombolysis for acute myocardial infarction
24. Initial platelet activity may predict efficacy after chronic oral glycoprotein IIb/IIIa blockade: Should we consider uniform treatment regimens?
25. A prospective multicenter study to determine the optimal level of platelet inhibition with GP IIb/IIIa inhibitors in patients undergoing coronary intervention - The GOLD study
26. Platelet inhibition by sertraline and N-desmethylsertraline: A possible missing link to explain benefits of selective serotonin reuptake inhibitors in depressed patients after acute coronary events